Functional class in patients with heart failure is associated with the development of diabetes

被引:71
作者
Tenenbaum, A [1 ]
Motro, M
Fisman, EZ
Leor, J
Freimark, D
Boyko, V
Mandelzweig, L
Adler, Y
Sherer, Y
Behar, S
机构
[1] Chaim Sheba Med Ctr, Neufeld Cardiac Res Inst, Cardiac Rehabil Inst, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Neufeld Cardiac Res Inst, Bezafibrate Infarct Prevent Study Coordinating Ct, IL-52621 Tel Hashomer, Israel
关键词
D O I
10.1016/S0002-9343(02)01530-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: Recent reports suggest that decreased functional capacity in patients with heart failure may be associated with abnormalities in glucose metabolism. We followed patients with coronary artery disease who participated in the Bezafibrate Infarction Prevention study to determine the incidence of diabetes by baseline functional status during a 7.7-year follow-up. METHODS: The sample comprised 2616 nondiabetic patients aged 45 to 74 years with a fasting blood glucose level <7 mmol/L (126 mg/dL). They were divided into three groups by New York Heart Association (NYHA) criteria: class I (n = 1986 patients), class II (n = 518), and class III (n = 112). The detection of a fasting blood glucose level greater than or equal to7 mmol/L during follow-up was. defined as the criterion for the development of diabetes. RESULTS: The study groups had similar demographic and clinical characteristics, except that patients with symptomatic heart failure (NYHA class II or III) were more likely to have angina. During follow-up, diabetes developed in 25 patients (13%) in NYHA class I, 76 (15%) in class II, and 22 (20%) in class III (P for trend = 0.05). At the last visit, patients in NYHA class III were twice as likely (17% [n = 19]) to have fasting blood glucose levels greater than or equal to7 mmol/L as those in NYHA class I (7.8% [n = 154]) or class II (8.7% [n = 45]) (P = 0.005). In a multivariate analysis, NYHA class III was associated with a 1.7-fold (95% confidence interval [CI]: 1.1 to 2.6) increase in the rate of development of diabetes, but NYHA class 11 was not (hazard ratio = 1.0; 95% CI: 0.8 to 13). CONCLUSION: Among patients with coronary artery disease, advanced heart failure (N-YHA class III) is associated with a significantly increased risk of developing diabetes during a 6- to 9-year follow-up. (C) 2003 by Excerpta Medica Inc.
引用
收藏
页码:271 / 275
页数:5
相关论文
共 33 条
[1]  
Amato L, 1997, DIABETES METAB, V23, P213
[2]   High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men -: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study [J].
Balkau, B ;
Shipley, M ;
Jarrett, RJ ;
Pyörälä, K ;
Pyörälä, M ;
Forhan, A ;
Eschwège, E .
DIABETES CARE, 1998, 21 (03) :360-367
[3]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[4]  
Burchfiel Cecil M., 1995, Annals of Epidemiology, V5, P33, DOI 10.1016/1047-2797(94)00038-U
[5]   Rapid rise in the incidence of type 2 diabetes from 1987 to 1996 - Results from the San Antonio Heart Study [J].
Burke, JP ;
Williams, K ;
Gaskill, SP ;
Hazuda, HP ;
Haffner, SM ;
Stern, MP .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (13) :1450-1456
[6]   Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes [J].
Drivsholm, T ;
Ibsen, H ;
Schroll, M ;
Davidsen, M ;
Borch-Johnsen, K .
DIABETIC MEDICINE, 2001, 18 (02) :126-132
[7]   Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: A marker for a worse prognosis [J].
Fisman, EZ ;
Motro, M ;
Tenenbaum, A ;
Boyko, V ;
Mandelzweig, L ;
Behar, S .
AMERICAN HEART JOURNAL, 2001, 141 (03) :485-490
[8]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[9]   RATIONALE AND DESIGN OF A SECONDARY PREVENTION TRIAL OF INCREASING SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND REDUCING TRIGLYCERIDES IN PATIENTS WITH CLINICALLY MANIFEST ATHEROSCLEROTIC HEART-DISEASE (THE BEZAFIBRATE INFARCTION PREVENTION TRIAL) [J].
GOLDBOURT, U ;
BEHAR, S ;
REICHERREISS, H ;
AGMON, J ;
KAPLINSKY, E ;
GRAFF, E ;
KISHON, Y ;
CASPI, A ;
WEISBORT, J ;
MANDELZWEIG, L ;
ABINADER, E ;
AHARON, L ;
BRAUN, S ;
DAVID, D ;
FLICH, M ;
FRIEDMAN, Y ;
KRISTAL, N ;
LEIL, N ;
MARKIEWICZ, W ;
MARMOR, A ;
PALANT, A ;
PELLED, B ;
RABINOWITZ, B ;
REISIN, L ;
ROGUIN, N ;
ROSENFELD, T ;
SCHLESINGER, Z ;
SCLAROVSKY, S ;
SHERF, L ;
TZIVONI, D ;
ZAHAVI, I ;
ZION, M ;
BRUNNER, D ;
FRIDENSOHN, A ;
JAFARI, J ;
OSTFELD, B ;
ROCHFLEISH, S ;
SCHNEIDER, H ;
KHALID, S ;
NARINSKY, R ;
ROTZAK, R ;
VITRAI, J ;
PELLED, B ;
PARDU, J ;
LANIADO, S ;
ESHCHAR, Y ;
ARDITI, A ;
BOTWIN, S ;
ROGUIN, N ;
YAHALOM, M .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (11) :909-915
[10]   Diabetes and cardiovascular disease - A statement for healthcare professionals from the American Heart Association [J].
Grundy, SM ;
Benjamin, IJ ;
Burke, GL ;
Chait, A ;
Eckel, RH ;
Howard, BV ;
Mitch, W ;
Smith, SC ;
Sowers, JR .
CIRCULATION, 1999, 100 (10) :1134-1146